Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process

Acquisitions

▤ Summary

Seer announced that its special committee finished reviewing unsolicited acquisition proposals and rejected both bids. The board concluded that selling the company would undervalue Seer and its future prospects. Seer said it will continue as an independent public company and focus on demand for its proteomics platform. The company highlighted its Proteograph product suite and its position in deep, unbiased proteomics.

◇ AskAI Classifications

Sectors
Life Sciences and Pharmaceutical Life Sciences Management
Functions
Business Intelligence and Analytics BI Analytics

▦ Linked Companies

Seer
$10M to $25M